文献速递流行病学与生物统计真实世界研究与卫生经济

共享个体参与者水平数据的临床试验组合的二次利用与学术影响:横断面研究

Secondary use and scholarly impact of a portfolio of clinical trials with shared individual participant level data: cross sectional study.
PubMed 文献 · BMJ · 2026-09-02

该研究评估了强生公司资助、通过YODA项目平台共享个体参与者水平数据(IPD)的336项临床试验中二次出版物的数量、时间、特征及学术影响。研究发现265项试验(79%)至少产生一篇二次出版物,共1167篇,其中外部研究者发表209篇(17.9%);外部出版物更多为汇总分析、预测模型和算法开发,期刊影响因子和Altmetric关注度更高,但年引用数更低,被临床指南和政策文件引用的比例也较低。结论提示结构化数据共享机制可促进临床试验数据的二次利用并提升科学价值。

要点

  • 79%的共享IPD试验产生了二次出版物,外部研究者占比随时间增长超过50%。
  • 外部出版物更多涉及汇总分析、预测建模和算法开发,发表期刊影响因子更高但年引用数更低。
  • 外部出版物被临床指南和政策文件引用的比例显著低于内部出版物。

核心结论

  • 通过数据共享平台提供IPD的临床试验多数产生了二次研究,外部研究者出版物占比随时间增加。
  • 结构化数据共享机制可能支持临床试验数据的额外二次利用并增强科学价值。

研究设计与样本

  • 横断面研究,基于Yale University Open Data Access(YODA)项目平台。
  • 纳入强生公司资助、截至2021年通过YODA平台可外部共享IPD且有完整同行评议主要结局发表物的临床试验,共336项。

主要发现

  • 336项试验中265项(79%)有至少一篇二次出版物,共1167篇,其中外部出版物209篇(17.9%)。
  • 外部出版物中190篇报告数据获取机制,161篇(85%)通过数据共享平台获取,157篇(83%)通过YODA项目。
  • 外部出版物中汇总分析占72%(151/209),内部为55.7%(534/958),P<0.001。
  • 外部出版物中预测或预后建模占51.7%(108/209),内部为33.6%(322/958),P<0.001。
  • 外部出版物期刊影响因子中位数6.7(IQR 3.4-16.6),内部为4.6(2.9-10.2),P=0.002;年Altmetric Attention Score中位数2.1(0.7-7.1)vs 0.6(0.3-2.3),P<0.001;年引用数中位数2.7(1.1-5.6)vs 3.4(1.6-7.5),P<0.001。

临床怎么用

  • 数据共享平台可促进外部研究者对试验IPD的二次利用,增加二次研究产出。
  • 外部二次研究在预测建模和算法开发方面贡献突出,但被指南和政策引用较少,需关注其转化价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the number, timing, characteristics, and scholarly impact of secondary publications generated using individual participant level data (IPD) from a portfolio of clinical trials shared with external investigators through a data sharing platform. DESIGN: Cross sectional study. SETTING: Yale University Open Data Access (YODA) Project platform. PARTICIPANTS: Johnson & Johnson sponsored clinical trials listed on the YODA Project platform with IPD available for external sharing through 2021 and with a full length, peer reviewed publication (that is, primary publication) reporting primary endpoint results by the original trial investigators. MAIN OUTCOME MEASURES: Number, timing, research objectives, analysis type, and scholarly impact of secondary publications using IPD from these trials identified through Web of Science citation searches of primary publications through June 2025. Scholarly impact metrics included journal impact factor, annual citation count, and annual Altmetric Attention Score. Secondary publications were classified as internal (authored by at least one original trial investigator) or external. RESULTS: Among 336 eligible trials, 265 (79%) had at least one associated secondary publication, totalling 1167 publications, of which 209 (17.9%) were external. Among external publications with a reported data access mechanism (n=190; 91%), most obtained access through data sharing platforms (n=161; 85%), primarily the YODA Project (n=157; 83%). Over time, the proportion of external publications increased steadily, exceeding 50% of all secondary publications by year 11 and thereafter. Compared with internal publications, external publications were more frequently pooled analyses (151/209 (72%) v 534/958 (55.7%); P<0.001) and involved predictive or prognostic modelling (108/209 (51.7%) v 322/958 (33.6%); P<0.001), development of statistical models or algorithms (60/209 (29%) v 114/958 (11.9%); P<0.001), and validation of existing methods, models, or risk scores (32/209 (15%) v 66/958 (6.9%); P<0.001). Compared with internal publications, external publications were published in journals with higher impact factors (median 6.7 (interquartile range 3.4-16.6) v 4.6 (2.9-10.2); P=0.002) and had higher annual Altmetric Attention Scores (median 2.1 (0.7-7.1) v 0.6 (0.3-2.3); P<0.001) but had lower annual citation counts (median 2.7 (1.1-5.6) v 3.4 (1.6-7.5); P<0.001) and were less likely to be cited in clinical guidelines (21/184 (11%) v 235/805 (29.2%); P<0.001) or policy documents (14/184 (8%) v 206/805 (25.6%); P<0.001). CONCLUSIONS: Most trials in this portfolio of clinical trials, for which IPD were available through a data sharing platform, generated secondary research by both original trial investigators and external investigators. External investigators most often accessed data through the data sharing platform, and their publications accounted for an increasingly larger proportion of secondary publications over time. These findings suggest that structured data sharing mechanisms may support additional secondary use of clinical trial data and further enhance the scientific value of clinical trials.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Taherifard E, Mooghali M, Hakimian HR, et al. Secondary use and scholarly impact of a portfolio of clinical trials with shared individual participant level data: cross sectional study. BMJ. 2026. PMID: 42686366. doi:10.1136/bmj-2026-100460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。